Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Sirion Therapeutics completes merger with Sytera

Aug. 22, 2006

Visual acuity stabilization eight weeks after a single dose of Sirna-027

Aug. 17, 2006

Ophthalmic ciclosporin to be tested for the treatment of ocular rosacea in new clinical trial

Aug. 14, 2006

Activation of EGFR in optic nerve astrocytes mediates optic nerve damage in rats

Aug. 14, 2006

MacuSight's ophthalmic formulation of sirolimus cleared for phase I studies

Aug. 10, 2006

Allergan patents novel prostanoid EP2 agonists for glaucoma

Aug. 9, 2006

ISTA inlicenses North American rights to ophthalmic bepotastine

Aug. 8, 2006

Santen files for Japanese approval of DE-085

Aug. 3, 2006

AK-1015 cleared to begin pivotal trial for ocular anesthesia

Aug. 3, 2006

Novel prostanoid EP2 agonists for glaucoma emerge from Allergan

July 27, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...